Literature DB >> 11800523

Humoral markers of severity and prognosis of critical illness.

E S Nylén1, A A Alarifi.   

Abstract

Despite the considerable advances made in understanding the pathophysiology of systemic inflammation during critical illness, clinical progress has been elusive as it remains a very deadly condition. Cortisol and thyroid hormone levels can be as predictive of outcome as the commonly used severity parameters (i.e. APACHE). Indeed, levels of endocrine humoral substances such as arachidonic acids, nitric oxide, endothelin, calcitonin precursors, leptin and adenosine correlate with the severity and outcome of critical illness. Furthermore, calcitonin precursors represent a potentially new hormokine paradigm, being transcriptionally activated in all cells in response to infection. The cytokines are immune markers that often correlate with severity and outcome, but their release is transient. In contrast, the so-called acute phase proteins, such as C-reactive protein and serum amyloid A, are highly sensitive to inflammatory activity and can be important markers of severity and outcome. Leukocyte esterase, adhesion molecules, platelet activating factor and activated protein C are additional humoral immune markers; the replacement of the latter has been shown to be a promising therapeutic option. Natriuretic peptides are neurocrine humoral markers that have important cardiovascular implications. The level of macrophage migrating inhibitory factor, released by the pituitary, is elevated in sepsis and counteracts glucocorticoid action. Cellular markers to severe stress include the enhanced expression of protective substances in the form of heat shock proteins. High mobility group-1 is a DNA-binding protein and a late mediator of the inflammatory response. Apoptotic markers such as the soluble fas ligand are also elevated in inflammation. In summary, during critical illness, the endocrine, immune and nervous systems elaborate a multitude of humoral markers, the roles of which merit further scrutiny in order to improve therapeutic outcome. Copyright 2001 Harcourt Publishers Ltd.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11800523     DOI: 10.1053/beem.2001.0169

Source DB:  PubMed          Journal:  Best Pract Res Clin Endocrinol Metab        ISSN: 1521-690X            Impact factor:   4.690


  12 in total

1.  Procalcitonin induced cytotoxicity and apoptosis in mesangial cells: implications for septic renal injury.

Authors:  Magali Araujo; Sonia Q Doi; Carlos E Palant; Eric S Nylen; Kenneth L Becker
Journal:  Inflamm Res       Date:  2013-07-20       Impact factor: 4.575

Review 2.  Guiding the vaginal microbicide trials with biomarkers of inflammation.

Authors:  Raina N Fichorova
Journal:  J Acquir Immune Defic Syndr       Date:  2004-10       Impact factor: 3.731

Review 3.  Procalcitonin in sepsis and systemic inflammation: a harmful biomarker and a therapeutic target.

Authors:  Kenneth L Becker; Richard Snider; Eric S Nylen
Journal:  Br J Pharmacol       Date:  2009-11-27       Impact factor: 8.739

4.  Selective improvement of tumor necrosis factor capture in a cytokine hemoadsorption device using immobilized anti-tumor necrosis factor.

Authors:  Morgan V DiLeo; James D Fisher; Brianne M Burton; William J Federspiel
Journal:  J Biomed Mater Res B Appl Biomater       Date:  2011-01       Impact factor: 3.368

5.  A simple mathematical model of cytokine capture using a hemoadsorption device.

Authors:  Morgan V DiLeo; John A Kellum; William J Federspiel
Journal:  Ann Biomed Eng       Date:  2008-10-24       Impact factor: 3.934

6.  Continuous hemodiafiltration with PMMA Hemofilter in the treatment of patients with septic shock.

Authors:  Taka-Aki Nakada; Shigeto Oda; Ken-Ichi Matsuda; Tomohito Sadahiro; Masataka Nakamura; Ryuzo Abe; Hiroyuki Hirasawa
Journal:  Mol Med       Date:  2008 May-Jun       Impact factor: 6.354

7.  Alterations of leptin in the course of inflammation and severe sepsis.

Authors:  Michael Behnes; Martina Brueckmann; Siegfried Lang; Christian Putensen; Joachim Saur; Martin Borggrefe; Ursula Hoffmann
Journal:  BMC Infect Dis       Date:  2012-09-14       Impact factor: 3.090

8.  Effects of probiotics on serum levels of Th1/Th2 cytokine and clinical outcomes in severe traumatic brain-injured patients: a prospective randomized pilot study.

Authors:  Min Tan; Jing-Ci Zhu; Jiang Du; Li-Mei Zhang; Hua-Hua Yin
Journal:  Crit Care       Date:  2011-12-02       Impact factor: 9.097

9.  Endocrine emergencies in critically ill patients: Challenges in diagnosis and management.

Authors:  Sukhminder Jit Singh Bajwa; Ravi Jindal
Journal:  Indian J Endocrinol Metab       Date:  2012-09

10.  Erythropoietin and renin as biological markers in critically ill patients.

Authors:  Fabienne Tamion; Véronique Le Cam-Duchez; Jean-François Menard; Christophe Girault; Antoine Coquerel; Guy Bonmarchand
Journal:  Crit Care       Date:  2004-08-09       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.